Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Request a Policy / Feedback
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.31
    OpenPayerPolicy UpdatesNeurology/NeurosurgeryAvMed Amvuttra prior auth Coverage | OpenPayer
    Ask Trek AI about this page
    CurrentAvMedPolicy Pub. 100-2

    Amvuttra (vutrisiran) prior authorization for transthyretin amyloidosis

    Customize your policy alerts

    Sign up for AvMed Policy Pub. 100-2 alerts

    Get alerted when Policy Pub. 100-2 changes without checking for updates manually.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    This AvMed medical prior authorization/step-edit form governs coverage and authorization requirements for Amvuttra (vutrisiran) for members with transthyretin-mediated polyneuropathy or cardiomyopathy; it applies to providers seeking medical (non-pharmacy) benefit approval.

    Policy Summary
    PayerAvMed
    PolicyAmvuttra (vutrisiran) prior authorization for transthyretin amyloidosis
    Policy CodePolicy Pub. 100-2
    Change TypeNo material changes noted
    Effective Date
    Next Review Date
    Key ActionPrescribing physician must sign the prior authorization request and provide required clinical documentation to support each criterion.
    SourceLink
    POLICY UPDATE CHANGES

    No material clinical or coverage changes in this revision.

    25 mg q3mDosing
    6 or 12 moInitial auth

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    6 or 12 moReauth
    1 syringe/3 moQty limit

    Coverage Criteria for Amvuttra (vutrisiran)

    Initial Therapy (hATTR polyneuropathy)

    Covered when ALL of the following are met for hATTR polyneuropathy:

    Age and prescriber: Member is ≥ 18 years of age AND medication is prescribed by or in consultation with a neurologist.
    Diagnostic confirmation: Definitive diagnosis of hereditary transthyretin-mediated (hATTR) amyloidosis polyneuropathy (familial amyloid polyneuropathy) confirmed by BOTH: documented pathogenic TTR genetic mutation AND confirmation of amyloid deposits on tissue biopsy.
    Clinical evidence: Documentation of clinical signs and symptoms of polyneuropathy (e.g., peripheral sensorimotor polyneuropathy, autonomic neuropathy, motor disability) AND abnormal nerve conduction study or abnormal neurologic examination.
    Baseline functional status (any one required): Baseline polyneuropathy disability (PND) score ≤ IIIb OR baseline FAP Stage 1 or 2 (stage 1 = ambulatory; stage 2 = ambulatory with assistance).
    Treatment history and counseling: Member has NOT received a liver transplant AND member instructed to take the recommended daily allowance of vitamin A.

    Reauthorization (hATTR polyneuropathy)

    Reauthorization covered when ALL of the following that apply are met:

    Prior exposure: Member has previously received the requested medication.
    Ongoing disease status or response (one required): Documentation of continued PND score ≤ IIIb OR continued FAP Stage 1 or 2 OR evidence of positive clinical response (improved neurologic impairment, motor function, quality of life, or slowing of disease progression).

    Initial Therapy (ATTR cardiomyopathy)

    Covered when ALL of the following are met for ATTR-CM without polyneuropathy:

    Age and prescriber: Member is ≥ 18 years of age AND prescribed by or in consultation with a cardiologist.
    Cardiac diagnostic criteria: Echocardiogram or cardiac MRI suggestive of amyloidosis (left ventricular wall thickness ≥ 12 mm) AND history of heart failure with at least ONE of: prior heart failure hospitalization OR signs/symptoms of volume overload or requirement for diuretics; member must have NYHA class I, II, or III (if NYHA III, member must NOT meet the high-risk definition of NT-proBNP >3000 ng/L AND eGFR <45 mL/min/1.73 m2).
    Rule out light-chain amyloidosis: Light-chain (AL) amyloidosis must be excluded via serum free light chain assay and serum and urine immunofixation electrophoresis (sFLC, SIFE, UIFE).
    ATTR-CM confirmation (one required): Cardiac tissue biopsy demonstrating transthyretin (TTR) amyloid deposits OR nuclear scintigraphy (e.g., Tc-PYP) showing grade 2–3 cardiac uptake OR genetic testing confirming a pathogenic TTR mutation.

    Reauthorization (ATTR cardiomyopathy)

    Reauthorization covered when ALL of the following are met for ATTR-CM:

    Ongoing NYHA class: Member continues to have NYHA Functional Class I, II, or III heart failure.
    No combination therapy: Amvuttra is not used in combination with other transthyretin-targeting therapies.
    Evidence of benefit: Member has demonstrated positive clinical response or disease stability/mild progression documented by KCCQ score, 6-minute walk distance, frequency of cardiovascular hospitalizations, or cardiac biomarkers (e.g., NT-proBNP).

    The following conditions are not medically necessary and will result in denial of Amvuttra (vutrisiran) under the medical benefit: history of liver transplant; severe renal impairment or end-stage renal disease; moderate or severe hepatic impairment; New York Heart Association (NYHA) class IV heart failure; sensorimotor or autonomic neuropathy not related to hereditary transthyretin amyloidosis (for example, neuropathy due to monoclonal gammopathy or autoimmune disease); cardiomyopathy not related to transthyretin amyloidosis; or concurrent use of other specified transthyretin-targeting therapies or diflunisal.

    Coding, Dosing, and Quantity Limits

    Covered HCPCS CodesHCPCSCovered
    J0225Injection, vutrisiran, 1 mg (Amvuttra) - medical benefit
    Dosing / eligibility thresholds
    Recommended dosing25 mg administered by subcutaneous injection once every 3 months (25 mg/0.5 mL prefilled syringe; quantity limit: 1 syringe per 3 months, 4 doses/year)
    Initial authorization duration6 months for hATTR polyneuropathy; 12 months for ATTR cardiomyopathy
    Cardiac imaging thresholdEchocardiogram or cardiac MRI with left ventricular wall thickness ≥ 12 mm
    NYHA functional class inclusionNYHA class I, II, or III permitted; NYHA class IV excluded
    High‑risk NYHA III restrictionIf NYHA Class III, member must NOT be high risk (high risk defined as NT‑proBNP > 3000 ng/L and eGFR <45 mL/min/1.73 m2)

    Provider Requirements, Prior Authorization, and Documentation

    Prior Authorization

    Prior authorization required; prescriber signature and complete PA form

    Prior authorization is required for Amvuttra (vutrisiran) billed as J0225. The prescribing physician must sign and clearly print their name on the medical prior authorization/step-edit request (preprinted stamps are not valid) and submit the completed PA form with required clinical documentation; incomplete, incorrect, or illegible information may delay authorization.

    • Drug Requested: Amvuttra (vutrisiran) SQ (J0225)
    • Prescribing physician must sign and clearly print name on the request (preprinted stamps not valid)
    • Submit required clinical documentation per checklist for the chosen indication
    Step Therapy

    Step requirement — progression despite ≥90 days of a TTR stabilizer or intolerance

    For ATTR cardiomyopathy, approval requires documentation of disease progression despite at least 90 consecutive days of a transthyretin stabilizer, or documentation of intolerance/contraindication to both tafamidis and acoramidis; pharmacy paid claims must verify adherence when progression is claimed.

    Background and Clinical Context

    Transthyretin-mediated amyloidosis produces two principal clinical syndromes: hereditary transthyretin-mediated polyneuropathy (hATTR / FAP) and transthyretin amyloid cardiomyopathy (ATTR-CM). Assessment for polyneuropathy relies on neurologic evaluation and electrophysiology plus standardized disability staging (e.g., PND score or FAP stage). For cardiac disease, diagnosis and baseline assessment use imaging (echocardiography or cardiac MRI demonstrating increased left ventricular wall thickness), nuclear scintigraphy or biopsy for confirmation, and functional measures such as NYHA class, 6-minute walk distance, Kansas City Cardiomyopathy Questionnaire (KCCQ), and cardiac biomarkers (e.g., NT-proBNP).

    Verification of transthyretin etiology and exclusion of light-chain (AL) amyloidosis are required for cardiac indications. Initial authorization durations differ by phenotype: hATTR polyneuropathy initial authorizations are typically for 6 months, while ATTR-CM initial authorizations are typically for 12 months. Recommended dosing for Amvuttra is 25 mg administered subcutaneously once every 3 months.

    Definitions

    hATTR / FAP — diagnostic requirements
    DefinitionHereditary transthyretin‑mediated amyloidosis presenting with polyneuropathy (hATTR / familial amyloid polyneuropathy, FAP)
    Required diagnostic confirmationDefinitive diagnosis requires BOTH a documented pathogenic TTR genetic mutation AND confirmation of amyloid deposits on tissue biopsy
    Clinical evidence requiredPresence of clinical signs/symptoms (e.g., peripheral sensorimotor polyneuropathy, autonomic neuropathy, motor disability) AND abnormal nerve conduction study or neurologic exam findings
    Baseline functional statusBaseline PND score ≤ IIIb OR baseline FAP Stage 1 or 2 (stage 1 = ambulatory; stage 2 = ambulatory with assistance)
    Other requirementsMember must be ≥18 years old, not have received a liver transplant, and be instructed to take recommended daily allowance of vitamin A
    Policy Summary
    PayerAvMed
    PolicyAmvuttra (vutrisiran) prior authorization for transthyretin amyloidosis
    Policy CodePolicy Pub. 100-2
    Change TypeNo material changes noted
    Effective Date
    Next Review Date
    Key ActionPrescribing physician must sign the prior authorization request and provide required clinical documentation to support each criterion.
    SourceLink
    On This Page
    Coverage Criteria for Amvuttra (vutrisiran)Coding, Dosing, and Quantity LimitsProvider Requirements, Prior Authorization, and DocumentationBackground and Clinical ContextDefinitions
    Prior therapy requirement (one required): Documentation of worsening progression despite ≥ 90 consecutive days of a transthyretin stabilizer OR documentation of intolerance/contraindication to both tafamidis and acoramidis.

    Pharmacy paid claims MUST show adherence when claiming progression despite stabilizer.

    Concomitant therapy restriction: Amvuttra will NOT be used in combination with another therapy targeting transthyretin (e.g., Attruby, Vyndamax, Vyndaqel, Onpattro, Wainua).
    Baseline assessments: Provider must submit at least one baseline assessment such as Kansas City Cardiomyopathy Questionnaire (KCCQ) score, 6-minute walk distance, frequency of cardiovascular hospitalizations, or cardiac biomarkers (e.g., NT-proBNP).
    Vitamin A counseling: Member instructed to take the recommended daily allowance of vitamin A.
    • Progression must be shown by worsening signs/symptoms, increased NYHA class, heart-failure hospitalizations, or decline in quality of life (verified by chart notes)
    • If claiming progression despite stabilizer, pharmacy paid claims MUST show adherence to therapy
    • Alternatively, documentation of intolerance/contraindication to both tafamidis (Vyndamax/Vyndaqel) and acoramidis (Attruby) is acceptable
    Documentation Required

    Required supporting documentation: genetics, biopsy/imaging, neurophysiology, and baseline assessments

    Providers must submit supporting documentation to verify diagnosis and baseline disease status, including genetic testing, biopsy or diagnostic cardiac imaging, nerve conduction or neurologic exam results, baseline functional scores, and pharmacy paid claims where prior stabilizer use is relevant.

    • Genetic testing showing a pathogenic TTR mutation (for hATTR or as an ATTR-CM confirmation option)
    • Tissue biopsy demonstrating amyloid deposits or cardiac tissue biopsy confirming TTR amyloid; or nuclear scintigraphy (Tc‑PYP) grade 2–3 uptake for ATTR-CM
    • Nerve conduction study or neurologic exam results for polyneuropathy indications
    • Baseline assessments: PND score or FAP stage (polyneuropathy); KCCQ, 6-minute walk, CV hospitalization frequency, or NT‑proBNP (cardiomyopathy)
    • Pharmacy paid claims to verify adherence to prior transthyretin stabilizer when progression is asserted
    Denial Risk

    Triggers that may delay or deny authorization: incomplete form, missing diagnostics, or absent clinician signature

    Authorization may be delayed or denied if the PA form or supporting records are incomplete, incorrect, or illegible, if required labs/diagnostics or chart documentation supporting each checked criterion are not provided, or if an exclusion applies (e.g., history of liver transplant, severe renal/hepatic impairment, NYHA class IV, or concurrent prohibited TTR therapies).

    • Illegible or unsigned (by prescribing physician) PA requests can delay authorization
    • Missing required labs, diagnostics, chart notes, or baseline assessments for the indication may result in denial
    • Concurrent use of other specified TTR-targeting therapies or presence of listed exclusions (see exclusions) will prevent approval
    ATTR‑CM — diagnostic criteria
    DefinitionTransthyretin amyloid cardiomyopathy (ATTR‑CM), wild‑type or hereditary, causing cardiac amyloid disease
    Cardiac diagnostic criteriaEchocardiogram or cardiac MRI suggestive of amyloidosis (LV wall thickness ≥ 12 mm) plus history of heart failure with prior HF hospitalization or signs/symptoms of volume overload or diuretic requirement
    Confirmation (one required)Cardiac tissue biopsy showing TTR amyloid deposits OR nuclear scintigraphy (e.g., Tc‑PYP) grade 2–3 cardiac uptake OR genetic testing confirming a pathogenic TTR mutation
    Light‑chain amyloidosis exclusionLight‑chain amyloidosis must be ruled out by serum free light chain assay and serum/urine immunofixation electrophoresis (sFLC, SIFE, UIFE)
    NYHA and risk criteriaMember must have NYHA class I–III (if NYHA III, must NOT be high risk defined as NT‑proBNP >3000 ng/L and eGFR <45 mL/min/1.73 m2)